Autores: Sargas, C.; Ayala, R.;
Larráyoz Ilundáin, María José; Chillon, M. C.; Carrillo-Cruz, E.; Bilbao-Sieyro, C.; Prados-de la Torre, E.; Martínez-Cuadron, D.; Rodríguez-Veiga, R.; Boluda, B.; Gil, C.; Bernal, T.; Bergua, J. M.; Algarra, L.; Tormo, M.; Martínez-Sánchez, P.; Soria, E.; Serrano, J.; Alonso-Domínguez, J. M.; García-Boyero, R.; Amigo, M. L.; Herrera-Puente, P.; Sayas, M. J.; Lavilla-Rubira, E.; Martínez-López, J.;
Calasanz Abinzano, María José; García-Sanz, R.; Pérez-Simon, J. A.; Gómez-Casares, M. T.; Sánchez-García, J.; Barragan, E. (Autor de correspondencia); Montesinos, P.
Resumen:
Simple Summary Next-Generation Sequencing (NGS) has provided a deeper genetic understanding of acute myeloid leukemia (AML) that has been recently incorporated into AML classification and risk-stratification guidelines. Single molecular analysis has become inefficient and molecular testing based on NGS is emerging as an irreplaceable diagnostic tool in clinical settings. The PETHEMA cooperative group has constituted a nationwide NGS network with centralized analysis in seven high-skilled laboratories. The study of molecular profiles in the real-life PETHEMA cohort supports the increasing role of NGS on the clinical management of AML patients. Next-Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross-validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS-AML project; NCT03311815) with standardized NGS of consensus genes (ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and WT1) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co-occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia-related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies.
